Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.76 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.76 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.76 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14974274 | 0.82 | KCNN3 (0.72) | KCNN3KCNN1KCNN2PDE10ACCNE1 | |
| SCHEMBL902740 | 0.81 | KCNN3 (0.67) | KCNN3KCNN1KCNN2PDE10ACCNE1 | |
| SCHEMBL12953257 | 0.80 | KCNN3 (0.76) | KCNN3KCNN1KCNN2PDE10ACCNE1 | |
| SCHEMBL13117302 | 0.76 | KCNN3 (0.80) | KCNN3KCNN1KCNN2PDE10ACCNE1 | |
| SCHEMBL10085529 | 0.75 | PDE10A (0.79) | PDE10A | |
| SCHEMBL17926547 | 0.72 | KCNN3 (0.68) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL13985944 | 0.71 | KCNN3 (0.77) | KCNN3KCNN1KCNN2PDE10ACDK2 | |
| SCHEMBL5456487 | 0.71 | KCNN3 (0.73) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL5447969 | 0.71 | KCNN3 (0.66) | KCNN3KCNN1KCNN2PDE10ACDK2 | |
| SCHEMBL4201923 | 0.70 | KCNN3 (0.75) | KCNN3KCNN1KCNN2PDE10ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621926-B1 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | PDE12, PDE5A, PDE4A | KCNN3 1293/4885KCNN1 1432/4885KCNN2 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.